Crossmark

Polypharmacy in patients with multiple sclerosis: a gender-specific analysis

Published Online: 2019-05-27

Published Print: 2019-12

Authors

Frahm, Niklas http://orcid.org/0000-0002-4655-774X
Hecker, Michael http://orcid.org/0000-0001-7015-3094
Zettl, Uwe Klaus
License Information

Text and Data Mining valid from 2019-05-27

Version of Record valid from 2019-05-27
More Information

Article History

Received: 25 March 2019

Accepted: 17 May 2019

First Online: 27 May 2019

Ethics approval and consent to participate

: The study was approved by the Ethics Committee of the University of Rostock (approval number A 2014-0089) and conducted in accordance with the Declaration of Helsinki.

: With informed consent, MS patients attended the examination.

: MH received speaking fees and travel funds from Bayer HealthCare, Biogen, Novartis, and Teva. UKZ received research support as well as speaking fees and travel funds from Almirall, Bayer HealthCare, Biogen, Merck Serono, Novartis, Sanofi, and Teva. NF received travel funds from Novartis.

Document is current